FRA:UDD (Australia)
Â
Business Description
Prescient Therapeutics Ltd
NAICS : 325412
Compare
Compare
Traded in other countries / regions
PTX.AustraliaUDD.GermanyPSTTF.USA Description
Prescient Therapeutics Ltd is a clinical-stage oncology company. The company develops novel compounds for the treatment of a range of cancers in Australia. Its product in the pipeline includes OmniCAR; PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.95 | |||||
| Piotroski F-Score | 3/9 | |||||
| Beneish M-Score | -4.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 20.6 | |||||
| 3-Year EPS without NRI Growth Rate | 20.6 | |||||
| 3-Year FCF Growth Rate | 25.6 | |||||
| 3-Year Book Growth Rate | -10.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 71.03 | |||||
| 12-1 Month Momentum % | 281.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.61 | |||||
| Quick Ratio | 17.61 | |||||
| Cash Ratio | 15.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -27.5 | |||||
| ROA % | -26.63 | |||||
| ROIC % | -160.89 | |||||
| ROC (Joel Greenblatt) % | -542.65 | |||||
| ROCE % | -27.41 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.9 | |||||
| Price-to-Tangible-Book | 5.5 | |||||
| EV-to-EBIT | -14.91 | |||||
| EV-to-EBITDA | -14.92 | |||||
| EV-to-FCF | -17.67 | |||||
| Price-to-Net-Current-Asset-Value | 5.5 | |||||
| Price-to-Net-Cash | 5.5 | |||||
| Earnings Yield (Greenblatt) % | -6.71 |
